Emerging Opportunities with Cannabinoids

Published by: Espicom Healthcare Intelligence

Published: Sep. 12, 2008 - 74 Pages

Table of Contents

Introduction

CB1,agonists

Cannabinoid agonists and CB1 specific agonists in development

Emesis

Market size and growth

growth drivers and market risks

current and future drug therapies

Cachexia

Market size and growth

Population forecasts

HIV/AIDS cachexia:

Forecast number of patients with cachexia associated with HIV/AIDS (‘000s)

Cancer cachexia:

growth drivers and market risks

HIV/AIDS cachexia:

Cancer cachexia:

current and future drug therapies

HIV/AIDS cachexia:

Cancer cachexia:

Pain

Market size and growth

Neuropathic pain:

Population forecasts

Growth drivers and market risks

Current and future drug therapies

Traumatic brain injury

Cancer

CB2 agonIsts

CB2 agonists in development

Pain and inflammation

Market size and growth

Population forecasts

Forecast number of patients with osteoarthritis (millions)

growth drivers and market risks

current and future drug therapies

Blood cancers

CB1 antagonIsts

CB1 antagonists in development

Obesity

Market size and growth

Increasing prevalence of obesity in the US

Rates of obesity in five major European countries

Population forecasts

Forecast number of obese adults in millions

growth drivers and market risks

current and future agents

Smoking cessation

Market size and growth

Trends in per capita cigarette consumption

Population forecasts

Forecast number of smokers (in millions) in major developed markets

growth drivers and market risks

current and future agents

Schizophrenia

Parkinson’s disease

CB2 antagonists

Endocannabinoid deactivation Inhibitors

FAAH inhibitors in development

drug ProfileEs

Acomplia (rimonabant)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast Acomplia sales by use (US$ millions):

competitor ratio analysis

taranabant (MK 0364)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast taranabant sales by use (US$ millions):

competitor ratio analysis

otenabant (CP-945,598)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast otenabant sales by use (US$ millions):

competitor ratio analysis

ibipinabant (BMS-646256; SLV-319)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast ibipinabant sales by use (US$ millions):

Competitor ratio analysis

surinabant (SR-147778)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

competitor ratio analysis

Marinol (dronabinol)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Marinol Dose: Response Frequency and Adverse Experiences*

(N = 750 treatment courses)

cachexia in aIds patients:

Management/clinical expertise

Competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast Marinol sales by use (US$ millions):

competitor ratio analysis

Cesamet (nabilone)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

Forecast Cesamet sales by use (US$ millions):

competitor ratio analysis

Sativex (tetrahydrocannabinol and cannabidiol)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

Sativex development overview

sales forecasts and assumptions

Forecast Sativex sales by use (US$ millions):

competitor ratio analysis

cannabinor (PRS-211,375)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

competitor ratio analysis

KN38-7271

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

competitor ratio analysis

drinabant (AVE 1625)

novelty/rationale for mechanism of action

Proof of concept/clinical data

Management/clinical expertise

competition within the marketplace/gaining share of voice

risks associated with developing a drug within a therapeutic class

filings and approval

sales forecasts and assumptions

competitor ratio analysis

CRA analysIs

Methodology

Overview

Cannabinoid agonists

CRA for cannabinoid agonists

CB1 antagonists

CRA for CB1 antagonists

Cannabinoids on the market and in development

Appendix I

Abbreviations

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.